INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Quinsair® (levofloxacin hemihydrate) offers a well-established tolerability profile1

In a study comparing the efficacy and safety of Quinsair to tobramycin inhaled solution (TIS), Quinsair demonstrated an overall tolerability profile similar to tobramycin inhaled solution.2

  • Dysgeusia was a common adverse reaction.2-4
  • Dysgeusia had no apparent impact on adherence to Quinsair2
  • 95.5% of patients taking Quinsair completed treatment vs 99.1% of placebo-assigned patients, with similar reasons for discontinuation between treatment groups5

 

ADVERSE REACTIONS WITH AT LEAST A POSSIBLE CAUSAL RELATIONSHIP WITH QUINSAIR1



For the full list of Adverse Events, please see the UK Summary of Product Characteristics or the Ireland Summary of Product Characteristics.


1. Quinsair® Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/32009. Accessed March 2018.
2. Elborn JS, et al. J Cyst Fibros. 2015;14:507-14.
3. Geller DB, et al. Am J Respir Crit Care Med. 2011;183:1510-16.
4. Elborn JS, et al. J Cyst Fibros. 2016; 15: 634-40.
5. Flume PA, et al. J Cyst Fibros. 2016;15:495-502.